Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558386 · ClinicalTrials.gov registry record
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
A clinical trial of Myelodysplastic Syndromes and Hematopoietic Cell Transplant, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- 92
- Enrollment target
- 6
- Study locations
NCT03558386: Completed study of Myelodysplastic Syndromes and Hematopoietic Cell Transplant, sponsored by Center for International Blood and Marrow Transplant Research.
NCT03558386 is a study of Myelodysplastic Syndromes and Hematopoietic Cell Transplant that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 92 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (68% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03558386, a study of Myelodysplastic Syndromes and Hematopoietic Cell Transplant, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
Primary Outcome
The primary objective is to compare the change in long-term post-HCT QOL (in particular physical function and fatigue) for transplant recipients ≥65 years old to those 55-64 years old as measured by the assessment and when the assessment occurred at a post-HCT timepoint.
Conditions Studied
Interventions
- BEHAVIORAL ePRO survey
Study Locations (6)
California
- Stanford University - Stanford
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University - Columbus
Wisconsin
- Froedtert Memorial Lutheran Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2019-11-15 |
What the finished NCT03558386 record still lists
NCT03558386 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which ePRO survey is the first listed.
NCT03558386 lists 6 locations in 6 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT03558386 about?
NCT03558386 is a clinical study titled "Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes". This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
What is the current status of trial NCT03558386?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2018-07-23. Estimated completion is 2019-11-15.
What conditions does trial NCT03558386 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Hematopoietic Cell Transplant.
What interventions are being tested in trial NCT03558386?
The interventions under investigation include: ePRO survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT03558386?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03558386 being conducted?
This trial has 6 study locations across California, Florida, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03558386's enrollment target sits among peer trials
92 59th of 173 higher than 114 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI